GPC Biotech Plans Restructuring To Cut Costs Following SPARC Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
German firm is planning workforce reductions after satraplatin did not show a survival benefit in prostate cancer patients
You may also be interested in...
More Satraplatin Pain For GPC As Other Shoe Drops
Celgene backs out of overseas deal for failed prostate-cancer chemo.
More Satraplatin Pain For GPC As Other Shoe Drops
Celgene backs out of overseas deal for failed prostate-cancer chemo.
GPC Biotech To Cut 38 Percent Of Workforce
Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.